| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |